| Literature DB >> 26911349 |
Rika Yuliwulandari1,2, Retno Wilujeng Susilowati3, Britanto Dani Wicaksono2, Kencono Viyati3, Kinasih Prayuni2, Intan Razari2, Erna Kristin4, Eva Sri Diana5, Suci Setiawati5, Aziza Ariyani5, Surakameth Mahasirimongkol6, Hideki Yanai7, Taisei Mushiroda8, Katsushi Tokunaga9.
Abstract
Drug-induced liver injury (DILI) is the most common adverse drug reaction in the treatment of tuberculosis (TB). Several studies showed that patients with TB and the slow-acetylator phenotype caused by NAT2 variants are highly susceptible to DILI caused by anti-TB drugs, hereafter designated AT-DILI. However, the role of NAT2 variants in AT-DILI has never been assessed for an Indonesian population. We recruited 50 patients with TB and AT-DILI and 191 patients with TB but without AT-DILI; we then used direct DNA sequencing to assess single-nucleotide polymorphisms in the coding region of NAT2. NAT2*6A was significantly associated with susceptibility to AT-DILI (P=7.7 × 10(-4), odds ratio (OR)=4.75 (1.8-12.55)). Moreover, patients with TB and the NAT2-associated slow-acetylator phenotype showed higher risk of AT-DILI than patients with the rapid- or intermediate-acetylator phenotypes (P=1.7 × 10(-4), OR=3.45 (1.79-6.67)). In conclusion, this study confirms the significance of the association between slow-acetylator NAT2 variants and susceptibility to AT-DILI in an Indonesian population.Entities:
Mesh：
Substances：
Year: 2016 PMID： 26911349 DOI： 10.1038/jhg.2016.10
Source DB: PubMed Journal: J Hum Genet ISSN： 1434-5161 Impact factor: 3.172